COSCIENS Biopharma Business Summary

COSCIENS Biopharma Inc. (CSCIF) is a specialty life science company that generates revenue through two primary business segments: Active Ingredient and Pharmaceutical. The Active Ingredient segment utilizes proprietary Pressurized Gas eXpanded (PGX) and oat extraction technologies to produce high-value natural compounds, including oat beta glucan, avenanthramides, and yeast-derived beta glucan, for the global cosmeceutical, nutraceutical, and veterinary health markets. The Pharmaceutical segment focuses on the commercialization of Macimorelin (Macrilen; Ghryvelin), the only FDA and EMA-approved oral diagnostic test for adult growth hormone deficiency, generating income through licensing agreements and sales royalties with global partners like Pharmanovia. COSCIENS competes directly with specialty biopharmaceutical firms such as Theratechnologies Inc., Aurinia Pharmaceuticals Inc., and Cardiff Oncology Inc., positioning itself as a niche leader in the integration of botanical biotechnology with specialized endocrine diagnostics. The company's leadership is currently spearheaded by Peter H. Puccetti, CFA, who serves as Chairman and Interim Chief Executive Officer following a strategic restructuring in late 2025. Puccetti brings over 30 years of investment expertise as the founder and Chief Investment Officer of Goodwood Inc., a prominent Canadian activist investment firm. The executive team includes Chief Financial Officer Giuliano La Fratta, a senior financial professional with extensive M&A experience from Aeterna Zentaris and CellCarta, and Chief Scientific Officer Michael Teifel, PhD, who leads the company’s R&D efforts with a 20-year background in endocrinology and oncology. Operations are managed by Michel Regnier, a professional engineer with over two decades of experience in pharmaceutical manufacturing. The board and investor base are notably influenced by Goodwood Inc., reflecting a strong focus on operational discipline and shareholder value creation following the 2024 merger of Aeterna Zentaris and Ceapro.